In-ovo vaccination (IO) is a widely adopted method in the global broiler poultry business. A common platform for IO vaccination is via the recombinant herpesvirus (rHVT), whose genome incorporates stable insertion(s) of genetic material to stimulate immunity against various diseases. In addition, more vaccines are being developed for in IO such as EVANOVO®, a live attenuated vaccine against avian coccidiosis (HIPRA, S.A.) and GUMBOHATCH®, a live immune complex vaccine against Infectious Bursal Disease (IBD). 

Combining IO vaccination against coccidiosis with other vaccines could optimize and minimize hatchery vaccination processes without compromising the immunogenicity of the co-administered vaccines. 

The objective of this study was to assess the safety and immunogenicity of the co-administration of EVANOVO®, GUMBOHATCH® and a rHVT ND vaccine when mixed before IO administration to 18-day-old broiler embryonated eggs.